Pharmaceuticals

I-Mab Expands U.S. Footprint with New R&D Site in San Diego

-  I-Mab will strengthen its global R&D presence, with a new world-class R&D and operational site, located in the heart of the rapidly growingSan Diego biotech hub -  The new site will complement I-Mab's Global Clinical Development site in Gaithersburg, Maryland to form an integrated I-Mab US R&...

2021-10-22 20:00 1682

2021 Bio-enzyme Application Explorer Summit held in Chengdu

The event focuses on innovation and development of biochemical pharmaceuticals CHENGDU, China, Oct. 22, 2021 /PRNewswire/ -- The biochemical pharmaceutical industry is facing unprecedented opportunities and challenges with the changing economic and policy environment inChina and abroad. On Octobe...

2021-10-22 14:23 1297

Specialised Therapeutics Enters into a New Supply and Distribution Agreement with Incyte to Launch Two New Cancer Therapies, Tafasitamab and Pemigatinib, in Australia, New Zealand and Singapore

SINGAPORE, Oct. 21, 2021 /PRNewswire/ -- Independent pharmaceutical company Specialised Therapeutics Asia Pte Ltd (ST) will partner withIncyte Biosciences  International Sàrl,the Swiss-based affiliate of Incyte (NASDAQ:INCY), to launch and distribute two new medicines for its haematology and onc...

2021-10-22 09:00 1618

Kintor Pharma Announces PD-L1/TGF-β dual-targeting antibody (GT90008) Approved for Advanced Solid Tumour Clinical Trial in China

SUZHOU, China, Oct. 21 , 2021 /PRNewswire/ -- Kintor Pharmaceutical Limited ("Kintor Pharma", HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, announced that the clinical trial of PD-L1/TGF-β dual-targeting antibody (GT90008) fo...

2021-10-21 22:33 2245

INOVIO Announces Collaboration with Colombia; Memorandum of Understanding Focuses on Protecting Against COVID-19 and Supporting Broader Health Preparedness Initiatives

Memorandum of Understanding builds on recent regulatory authorization from INVIMAto conduct INNOVATE Phase 3 trial for INO-4800, INOVIO's COVID-19 vaccine candidate,in Colombia Colombia authorization augments recent regulatory authorizations from Brazil, the Philippines and Mexico to commence it...

2021-10-21 20:00 2877

Luoxin Pharmaceutical signs licensing agreement with Austria-based Marinomed Biotech AG for Budesolv® Budesonide Nasal Spray

SHANGHAI, Oct. 21, 2021 /PRNewswire/ -- Shandong Luoxin Pharmaceutical Group Stock Co., Ltd. (''Shandong Luoxin''), a subsidiary of Luoxin Pharmaceutical Group Stock Co., Ltd. ("Luoxin Pharmaceutical" or "the company")    , signed a licensing agreement withAustria-based Marinomed Biotech AG ("Mar...

2021-10-21 15:58 1313

IND Application for Phase III Clinical Study of Anti-HER2 Bispecific Antibody KN026 was Officially Accepted by CDE

SUZHOU, China, Oct. 21, 2021 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) and CSPC Pharmaceutical Group Co., Ltd. (stock code: 1093.HK) jointly announced IND application for a phase III clinical study of recombinant humanized anti-HER2 bispecific antibody KN026 (KN026-306) was official...

2021-10-21 10:31 2390

GenFleet Announces First Patient Dosed in Phase Ib/II Trial of TGF-β R1 Inhibitor in Combination with PD-1 Inhibitor in Global Multi-center Research

PERTH, Australia and TAIPEI and SHANGHAI, Oct. 20, 2021 /PRNewswire/ -- GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, today announced the first patient with metastatic sigmoid adenocarcinoma has been dosed inPerth, Aus...

2021-10-21 08:05 1798

EVERSANA and Intouch Group join forces, adding the premiere digital-first agency network to the market leader in next generation commercialization

CHICAGO and KANSAS CITY, Mo., Oct. 20, 2021 /PRNewswire/ -- EVERSANA™, the pioneer of next generation commercial services to the global life sciences industry, andIntouch Group®, a full-service global agency network serving the pharmaceutical industry, today announced that they signed an agreemen...

2021-10-20 22:34 3347

BioVaxys Files US Patent Application for Pan-Sarbecovirus Vaccine

VANCOUVER, BC, Oct. 20, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV), (FRA:5LB), (OTCQB:BVAXF) ("BioVaxys" or "Company"), announced today that it has filed with the United States Patent & Trademark Office ("USPTO") a provisional patent application for its haptenized viral antigen va...

2021-10-20 21:24 4331

Senhwa Presents Positive Initial Data from Phase 2 Clinical Trial of Silmitasertib (CX-4945) in Moderate COVID-19 Patients At the ISIRV-WHO Conference

* Statistically significant 133% faster time to COVID-19 clinical symptoms recovery versus standard of care (SOC)/best supportive care. * Statistically significant 114% faster time to reach EQ-5D-5L Q6 ≥ 90% versus SOC/best supportive care. * Statistically significant 57% faster time to norm...

2021-10-20 20:52 1805

Island Pharmaceuticals to discuss its potential dengue fever preventative at Pharma Meeting Brazil & Latam 2021

MELBOURNE, Australia, Oct. 20, 2021 /PRNewswire/ -- Australian mid-clinical stage antiviral drug development company, Island Pharmaceuticals Ltd (ASX: ILA) is pleased to be attending Pharma Meeting Brazil & Latam 2021, this week and presenting to potential partners. Island's attendance at the co...

2021-10-20 18:00 1743

Xinhua Silk Road: 52nd Zhangshu National Traditional Chinese Materia Medica Trade Fair kicks off in E. China's Jiangxi

BEIJING, Oct. 20, 2021 /PRNewswire/ -- The 52nd Zhangshu National Traditional Chinese Materia MedicaTrade Fair opened in Zhangshu, a country-level city in eastChina's Jiangxi Province on Saturday.

2021-10-20 17:27 2495

Bill & Melinda Gates Foundation Commits up to $120 Million to Accelerate Access to COVID-19 Drug for Lower-Income Countries, Calls on Other Donors to Mobilize Resources

Financial commitment aims to secure dedicated, low-cost supply of molnupiravir, if the drug is authorized by regulators; builds on long-term efforts to increase access to tests, treatments, vaccines SEATTLE, Oct. 20, 2021 /PRNewswire/ -- The Bill & Melinda Gates Foundation announced today a comm...

2021-10-20 13:29 2061

CStone received China NMPA IND acceptance for lorlatinib in Chinese patients with ROS1-positive advanced NSCLC

SUZHOU, China, Oct. 20, 2021 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), a leading biopharmaceutical company focused on researching, developing, and commercializing innovative immuno-oncology therapies and precision medicines, today announced that the investigational new drug (...

2021-10-20 08:00 3001

Alterity Therapeutics Announces Expanded ATH434 Phase 2 Clinical Development Program

- Clinical trial to enroll patients with early-stage Multiple Systems Atrophy (MSA) - - Expanding bioMUSE Natural History Study - MELBOURNE, Australia and SAN FRANCISCO, Oct. 19, 2021 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology c...

2021-10-20 05:08 1663

Excelra Announces Addition of Sudip Nandy to its Board of Directors

HYDERABAD, India, Oct. 19, 2021 /PRNewswire/ -- Excelra, a leading Data and Analytics provider for Life Science organizations, announced the appointment of Sudip Nandy to the company's board of directors effective 1st October 2021. Mr. Nandy is an acclaimed business leader with over 30 years of e...

2021-10-19 21:00 6174

InnoCare Announces Approval of Clinical Trial of Novel SHP2 Allosteric Inhibitor ICP-189 in China

BEIJING, Oct. 19, 2021 /PRNewswire/ -- InnoCare Pharma (HKEX: 09969) announced today that the Company has received Investigational New Drug (IND) approval from the NMPA for itsSHP2 (Src Homology 2 domain containing protein tyrosine phosphatase) allosteric inhibitor ICP-189, which is the company's...

2021-10-19 12:56 1731

CARB-X Funds the 3rd Round of Debiopharm's Targeted Antibiotic Program to Combat Resistant N. gonorrhoeae Infections

LAUSANNE, Switzerland and BOSTON, Oct. 19, 2021 /PRNewswire/ -- Debiopharm ( www.debiopharm.com ), a Swiss-based global biopharmaceutical company announced today having been awarded the third phase funding to advance the development of its antibiotic program, Debio 1453...

2021-10-19 09:00 1685

Australian businesses invited to advance the future of healthcare technologies in the Medtronic APAC Innovation Challenge

SYDNEY, Oct. 19, 2021 /PRNewswire/ -- Medtronic plc (NYSE: MDT), the global leader in healthcare technology, invites Australian businesses to participate in the newly launchedMedtronic APAC Innovation Challenge (MAIC). Providing an opportunity for innovators in the region to pitch and advance the...

2021-10-19 06:51 3062
1 ... 215216217218219220221 ... 314